Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs, including antibodies, proteins, peptides and oligonucleotides. Its proprietary RaniPill capsule is designed to pass through the stomach and deliver a drug into the… From the company’s description.
In fiscal 2025, Rani Therapeutics Holdings, Inc. reported revenue of $1.63M, up 58.9% from fiscal 2024, and a net loss of $40.95M. Operations used $18.71M in cash. Over the twelve months to Jun 30, 2026, revenue was $4.88M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rani Therapeutics Holdings, Inc. does
In the company’s own words
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs, including antibodies, proteins, peptides and oligonucleotides. Its proprietary RaniPill capsule is designed to pass through the stomach and deliver a drug into the small-intestinal wall; the RaniPill GO accommodates up to 3 mg in microtablet form, while the RaniPill HC is designed for liquid payloads up to 200 microliters. The company develops its own oral drug candidates and partners with biopharmaceutical companies to adapt their medicines for oral delivery. Its programs include RT-114, a GLP-1/GLP-2 dual agonist for obesity, and RT-117, a hemophilia antibody program with Chugai Pharmaceutical; RT-114 is also partnered with ProGen. Rani reported a $10 million upfront payment under the Chugai collaboration in 2025. The company has no approved products or commercial product sales. Its website is www.ranitherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN JOSE, CA
- Fiscal year end
- December
- CIK
- 1856725
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rani Therapeutics Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rani Therapeutics Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rani Therapeutics Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rani Therapeutics Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rani Therapeutics Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”